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Abstract  
BACKGROUND: Percutaneous pulmonary valvuloplasty is well established treatment of choice in 
pulmonary valve stenosis.  
AIM: The aim of our study was to present our experience with the interventional technique, its 
immediate and mid-term effectiveness as well as its complication rate. 
MATERIAL AND METHODS: The study included 43 patients, where 33 (74%) of them were 
children between the age of 1 month and 15 years.  
RESULTS: The procedure was successful in 38 patients or 90%. Mean peak to peak transvalvular 
gradient was reduced from 91.2 mmHg (55-150 mmHg) to 39.1 mmHg (20-80 mmHg). Follow- up 
of patients was between 2 and 13 years and included echocardiographic evaluation of pulmonary 
valve gradient, right heart dimensions and function as well as assessment of pulmonary 
regurgitation. We experienced one major complication pericardial effusion in a 5 months old child 
that required pericardiocenthesis. Six patients (13.9%) required a second intervention. During the 
follow up period there was significant improvement of right heart function and echocardiography 
parameters. Mild pulmonary regurgitation was noted in 24 (55%) patients, and four (9%) patients 
developed moderate regurgitation, without affecting the function of the right ventricle. 
CONCLUSIONS: Percutaneous pulmonary valvuloplasty is an effective procedure in treatment of 
pulmonary stenosis with good short and mid-term results. 
 
 
 
 
 
 
Introduction 
 
Pulmonary valve stenosis (PS) is a heart 
valve disorder in which outflow of blood from the right 
ventricle of the heart is obstructed at the level of the 
pulmonic valve. Although most commonly diagnosed 
and treated in the pediatric population, individuals with 
more severe forms of PS are surviving into adulthood 
and require ongoing assessment and cardiovascular 
care. The prevalence of valvular pulmonary stenosis 
has been reported at 0.6 to 0.8 cases per 1000 live 
births. When associated with other congenital heart 
disorder, it occurs in approximately 50% of all born 
with some kind of congenital heart disease [1]. PS can 
be due to isolated valvular (90%), subvalvular, or 
peripheral (supravalvular) obstruction, or it may be 
found in association with congenital heart disorders of 
some other kind [2]. 
 
Valvular pulmonic stenosis 
Isolated valvular PS comprises approximately 
10% of all congenital heart disease. Typically, the 
valve commissures are partially fused and the 3 
leaflets are thin and pliant, resulting in a conical or 
dome-shaped structure with a narrowed central 
orifice. Poststenotic pulmonary artery dilatation may 
occur owing to "jet-effect" hemodynamics which is a 
good predictor for successful outcome of 
interventional treatment. With severe PS and 
decreased right ventricular chamber compliance, 
cyanosis can occur from right-to-left shunting if a 
concomitant patent foramen ovale, atrial septal defect, 
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or ventricular septal defect is present. 
 
Subvalvular pulmonic stenosis 
Subvalvular PS occurs as a narrowing of the 
infundibular or subinfundibular region, often with a 
normal pulmonic valve. This condition is present in 
individuals with tetralogy of Fallot and can also be 
associatedwith a ventricularseptaldefect (VSD).  
 
Peripheral pulmonary stenosis 
Peripheral pulmonary stenosis (PPS) can 
cause obstruction at the level of the main pulmonary 
artery, at its bifurcation, or at the more distal 
branches. PPS may occur at a single level, but 
multiple sites of obstruction are more common. PPS 
may be associated with other congenital heart 
anomalies such asvalvular PS, atrialseptaldefect 
(ASD), VSD, orpatentductusarteriosus (PDA); 20% of 
the patients with tetralogy of Fallot have associated 
PPS.  
Functional or physiologic PPS is a common 
cause of a systolic murmur in infants. It occurs in both 
premature and full-term infants; with time, the 
pulmonary artery grows, and the murmur usually 
disappears within a few months.  
Most children and adults with mild-to-
moderately severe pulmonic stenosis (PS) are 
asymptomatic. The ones with severe PS may 
experience exertional dyspnea and fatigue. In 
extremely rare cases, patients present with exertional 
angina, syncope, or sudden death. Peripheral edema 
and other typical symptoms occur with right heart 
failure. Cyanosis is present in those with significant 
right-to-left shunt via a patent foramen ovale, atrial 
septal defect, or ventricular septal defect [3].  
Up until 1982 this condition was treated 
surgically, the same year the technique of 
percutaneous balloon pulmonary valvuloplasty(BVP) 
was introduced by Kan et al. and since then it has 
become the established method of treatment of 
moderate and severe pulmonary stenosis in most 
cardiac centers in developed countries [4].Its minimal 
invasiveness and avoidance of sternotomy are some 
of the advantages over open surgical treatment. 
Potential disadvantages of this treatment are 
pulmonary valve re-stenosis, rupture of the pulmonary 
artery walls and post interventional high grade valve 
insufficiency. The successful use of the procedure in 
adults has been reported by several investigators [5-
19]. There are two major differences between balloon 
pulmonic valvuloplasty in adults and in children. When 
done in adults it does not seem as necessary as it is 
in children to select a balloon size substantially larger 
than the annulus of the pulmonic valve [20]. Second, 
the improvement in adults after the initial balloon 
dilation is usually maintained over a long term; 
whereas in children, there is a 19 % incidence of 
restenosis [21], particularly in newborns, which leads 
to possible redilatation of the valve. 
The aim of our study was to present the rate 
of success and complications in percutaneous 
pulmonary valvuloplasty done at our clinic during a 
period of eleven years, both in children and in adults. 
 
 
Methods 
 
From November 2003 to November 2014, 
forty three consecutive patients with moderate to 
severe PS, were considered for BVP. An inclusion 
criterion for BVP was the grade of the peak systolic 
pressure gradient across the pulmonic valve 
measured with Doppler echocardiography. We treated 
patients whose peak systolic gradient across the 
pulmonic valve was 50 mmHg or greater, with a 
normal cardiac index irrespective of symptoms. Thirty 
three children (1-15 years old), 1 adolescent and 9 
adults with PS were identified at our institution. The 
clinical characteristics of patients were reviewed. 
Physical examination, chest X-ray, electro-
cardiography and transthoracic echocardiography 
(TTE) were performed before the procedure. 
The upcoming technique of balloon dilatation 
of the pulmonary valve has been described thoroughly 
[22, 23].The intervention was done under general 
anesthesia with endotracheal intubation for children 
and local anesthesia for adults. Seldinger technique 
was used to insert 4-6 French pigtail catheters 
through the right or left femoral venous sheath along 
v. cava inferior into the right atrium, than in the right 
ventricle where right ventriculography was performed 
in left lateral views (Figure 1). 
 
Figure 1:  Right ventriculography 
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The lateral view of the right ventricular 
angiogram was used to measure the diameter of the 
orifice and annulus of the pulmonary valve from hinge 
to hinge point. The maximal diameter of the Tyshak II 
Balloon was purposely selected to be 1-2 mm larger 
than the one of the pulmonary valve annulus. This 
decision was made thanks to the reports of the 
usefulness of larger balloons [24-26] an attempt was 
made to achieve a balloon/annulus ratio between 1.2 
and 1.4 and in the last years we tend to decrease the 
ratio to 1.1-1.2 due to novel studies recommending 
lower ratio [27]. A multipurpose catheter was then 
introduced into the femoral venous sheath, advanced 
across the pulmonary valve with the tip positioned in 
one of the distal pulmonary artery branches. After the 
exchange wire was stabilized, balloon catheter was 
pulled back up to the point where the balloon’s middle 
portion was positioned across the pulmonary valve. 
At that exact moment the balloon was fully 
inflated within a few seconds and then quickly deflated 
(Figure 2). 
 
Figure 2: Balloon inflation through the pulmonary valve 
 
Right after the process of dilatation was 
performed, the multipurpose or MP catheter was 
pulled from the pulmonary artery into the right 
ventricle to measure the transvalvular pressure 
gradient. The balloon was reinflated to a larger 
diameter if the gradient had not substantially 
decreased. Finally, a pigtail catheter was inserted 
over the guide wire into the right side of the heart for 
additional right ventricular angiography. After the 
intervention, all adult patients were transferred to 
general wards and administered aspirin 3 mg/kg per 
day for 6 months. Control TTE was performed at one 
week and routinely assessed at one month after the 
procedure and once a year thereafter. 
Results 
 
Percutaneous pulmonary valvuloplasty was 
performed on 43 patients (age 1-66 years; 65% 
female) with congenital pulmonary stenosis (Table 1). 
Nine of the pediatric patients were associated with 
another congenital heart defect: atrial septal defect 
(ASD) in three, VSD in 5 and tetralogy Fallot 
associated with complete atrioventricular canal defect 
– CAVC and sy. Down in one patient. Thirty three 
(84%) of our patients had valvular stenosis, one 
patient had subvalvular, two had supravalvular and 
the rest combined. Twelve patients (28%) had 
symptoms of fatigue. Dyspnea and cyanosis were 
present in 6 (14%). Other common clinical 
presentations were chest pain and palpitations. 
Table 1: Demographic and characterization data of patients 
Patients 43 
Mean age 52.5 
Age groups  
Newborns 
Babies 
Children 
Adolescents 
Adults 
 
1 (2.31%) 
8 (19%) 
24 (55.81%) 
1 (2.3%) 
9 (21%) 
Gender 
Male  
Female 
 
15 (35%) 
28 (65%) 
Symptomatology 
Asymptomatic  
Symptomatic(dyspnea.fatigue)  
Symptomatic with cyanosis 
 
24 (58%) 
12 (28%) 
6 (14%) 
Transpulmonary valve pressure gradient 
50-70 mmHg 
70-100 mmHg 
>100 mmHg 
 
 
7 (16%) 
26(60%) 
10 (24%) 
Type of stenosis 
Valvular 
Subvalvular 
Supravalvular 
Combined  
 
36 (83%) 
1 (2.3%) 
2(4.7%) 
4(9.3%) 
 
Seven patients had moderate pulmonary 
stenosis with peak systolic gradient across the 
pulmonary valve of 50-70 mmHg, twenty six had 
severe pulmonary stenosis (70-100 mmHg) and ten 
patients were treated for pulmonary stenosis above 
100 mmHg.  
Pre interventional and post interventional data 
are shown in Figure 3. 
 
Figure 3: Decrease of mean transvalvular and right ventricular 
pressure gradient right after the intervention(PG of RV- pressure 
gradient in right ventricle; PG of PV- pressure gradient of pulmonary 
valve; BVP- balloon valvuloplasty) 
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The mean right ventricle systolic pressure 
before intervention was 106.7 mm/Hg and decreased 
to 56.2 mm/Hg after intervention. The mean peak to 
peak systolic pressure across pulmonary artery was 
91.2 mm/Hg and 39.1 mm/Hg right after intervention. 
In the patients presenting with cyanosis post-
intervention their saturation improved gradually and 
cyanosis decreased. Changes in the right ventricle in 
a matter of hypertrophy were noted in 27 patients and 
right ventricle dilatation in 5. Regression in right 
ventricular dimensions was observed in all patients. In 
88% of patients right heart dimension and function 
completely normalized at follow-up. Hypertrophy of 
right ventricular free wall remained in 5 patients, all of 
them belonging to the adult group. Mild pulmonary 
regurgitation was noted in 24 (55%), and 4 (9%) 
patients experienced moderate pulmonary 
regurgitation after the intervention. During our follow 
up period there was no incidence of severe pulmonary 
regurgitation (Figure 4). 
 
Figure 4: Pulmonary regurgitation before and after intervention 
 
We experienced one major complication - 
pericardial effusion in a 5 month old child that required 
pericardiocenthesis. Total of 6 patients (14%) required 
a second intervention, four after 2 years, and two after 
period of 3 years, due to restenosis of the pulmonary 
valve. 
Routine follow up was performed in most of 
the patients for a 5 year period after the intervention. 
The mean residual gradient in the final examination 
has dropped to 32.5 mmHg (Figure 5). 
 
Figure 5: Mean residual gradient of pulmonary artery valve at 
follow-up 
 
As stated previously re-intervention was 
undertaken in 5 patients. The re-intervention was 
unsuccessful for only one adult female patient whose 
transvalvular gradient remained 55 mmHg.  
Discussion 
 
This study demonstrates our experience with 
the percutaneous pulmonary valvuloplasty, its 
immediate and mid-term relief of stenosis of the 
pulmonary valve in most of the patients with moderate 
to severe pulmonary stenosis. The procedure not only 
improved the hemodynamic but also the clinical status 
of the patients with severe form of pulmonary 
stenosis. Being a nonsurgical procedure is its biggest 
advantage and is associated with less psychological 
trauma. Lower incidence in morbidity and mortality as 
well as shorter hospital days along with its cost 
effectiveness makes this technique as the treatment 
of choice for children and adults with valvular 
pulmonary stenosis.  
In our study, 90% of the patients had the 
transvalvular gradient decreased under 50mmHg with 
the procedure. The other patients required second 
intervention after 2-3 years. The second intervention 
was unsuccessful in one girl whose transvalvular 
gradient remained 55mmHg. All of patients that 
underwent second intervention had dysplastic 
pulmonary valve. 
Although rare complications during or 
immediately after this procedure are noted in several 
studies. Mortality rate and major complications have 
been found to be around 0.24% and 0.35% 
respectively in a multi-center study [28]. Most 
common symptoms are hypotension and bradycardia 
that tend to resolve quickly after balloon deflation. We 
experienced transient arrhythmias in patients during 
intervention with five (12%) of our patients. 
Another frequent association with PS is 
infundibular obstruction. This condition can usually be 
seen in older patients that are with higher degree of 
valvar obstruction, but it also tends to improve with 
time. Beta blockers have been used for significant 
infundibular obstruction > 50 mmHg after 
theintervention [29, 30]. Infundibular obstruction was 
present in 35% of our patients and was treated with 
beta blockers in the next 3-6 months after the 
procedure. At follow-up the infundibular gradients 
either diminished or disappeared. The infundibular 
gradients appeared to be more frequent with 
increasing age and severity of pulmonary valvar 
obstruction. Other complications reported in the 
literature are transient or permanent complete heart 
block, significant blood loss, seizures, cardiac arrest, 
cerebrovascular accidents, balloon rupture, rupture of 
tricuspid valve papillary muscle, and pulmonary artery 
tear. During the period represented in our study none 
of the complications above were experienced.  
As in the most catheterization based 
intervention, there is potential for femoral vein 
occlusion after pulmonary valvuloplasty. It is 
predominantly observed in 7-19% and more often in 
young infants [31]. 
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Pulmonary valve regurgitation is reported in 
41-88% of cases undergoing pulmonary balloon 
valvuloplasty[32;33;34]. In our study the incidence of 
pulmonary regurgitation was 38% and the 
regurgitation was mild, with only one patient (0.3%) 
developing moderate regurgitation. During the follow- 
up period none of our patients developed severe 
pulmonary regurgitation. 
In conclusion, balloon valvuloplasty is the 
treatment of choice in the management of moderate to 
severe pulmonary stenosis with excellent short- and 
mid-term results. Mortality and major complications 
are very rare. Pulmonary regurgitation is a 
complication with insignificant impact on right heart 
function at short and mid-term follow up. However, 
long term follow-up studies are needed, mostly for 
evaluation of pulmonary regurgitation. 
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